In a 3-year randomized open-label study, epalrestat was well tolerated and prevented the deterioration of median motor nerve conduction velocity, minimal F-wave latency and vibration perception threshold compared with the control group with DPN [118]
Cancer Lett 383:282294 Lamonte G, Tang X, Chen JL et al (2013) Acidosis induces reprogramming of cellular metabolism to mitigate oxidative stress
If GLP-1 drugs are to be used to treat a wide range of conditions, predicting who will benefit and who may be at risk becomes one of the most important, if not the most important, challenges
Two major clinical trials are the basis for most of what's known about these medications' weight-management effects: STEP 1 (68-week randomized study, adults without diabetes): semaglutide 2.4 mg produced an average loss of roughly 15% of body weight, versus about 2.4% with placebo, alongside a reduced-calorie diet and increased physical activity